The COVID-19 coronavirus pandemic has brought dramatic and fundamental changes to the way people run businesses. The global and domestic pharmaceutical industry also had to make adjustments to production blueprints promptly. Due to Dmytro Shymkiv, the Chairman of the Board of Directors of Darnytsia Group, the Darnytsia company has utilized all its resources to provide Ukrainians with vital drugs to the maximum in the context of the epidemic. Such efforts show no lack of medicines produced by Darnytsia within the period of coronavirus crisis in Ukraine.

The top manager Shymkiv also underlined that the domestic factory produces a range of drugs used in treating patients infected with Covid-19. First of all, it is about antipyretics, in particular, paracetamol. In 2019, this drug was manufactured 200% more than previously planned since the company's management clearly understood that Ukrainians would definitely feel the lack of such medicine. The Darnytsia company has been doing its best to ensure smooth delivery of this effective antipyretic drug to the pharmacy chains, which is included in the Covid-19 treatment protocol and recommended by WHO. In addition to paracetamol, the Darnytsia factory increased its capacity for the production of infusion solutions used in intensive care, and medicines used for significant lung damage, as well as drugs for treating the consequences of the thrombosis disease. At the same time, the Darnytsia pharmaceutical concern managed to preserve and multiply the main drug production to prevent dysfunctions and therapy of the cardiovascular and nervous systems. According to the statistics reported by Shymkiv, the vast majority of Ukrainians suffer from diseases of the central nervous system, heart and blood vessels, which lead to a significant increase in mortality rates.

Dmytro Shymkiv assured that the Darnytsia management approved the work plan in the context of the pandemic back in March last year. Now, the company's experts continue advancing the strategy, adapting it to new challenges. Owing to an integrated and sustainable approach, the company could protect its employees from the risk of Covid-19 disease as much as possible. Such an approach involved an obligatory vaccination against the influenza virus for all the Darnitsa Group’s employees, their medical insurance, and remote work for most of the office staff.